SecProbe.io

April 9 , 2013

Via E -mail
Mr. Scott Cormack
President and Chief Executive Officer
OncoGenex Pharmaceuticals, Inc.
1522 – 217th Place S.E., Suite 100
Bothell, Washington 98021

Re: OncoGenex Pharmaceuticals, Inc.
  Preliminary Proxy Statement on Schedule 14A
Filed on April 3 , 2013
  File No.  033-80623

Dear Mr. Cormack :

We have limited our review of your preliminary proxy statement  to the issue  we have
addressed in our comment .  Please respond to this letter by revising the proxy statement .  Where
you do not believe our comment applies  to your facts  and circumstances , please tell us why in
your response.

After reviewing the information you provide in response to our comment , we may have
additional comments.

1. We note proposal 5  where you are seeking approval to increase your number of
authorized shares of common stock from 25 million to 50 million shares .  Please
revise your disclosure to describe any  specific plans, arrang ements or understandings,
whether written or oral, to issue any of the shares of common stock  that will be newly
available .  If you have no  such plans, arrangement or understandings, please revise
your disclosure to so state.

We urge all persons who are r esponsible for the accuracy and adequacy of the disclosure
in the filing to be certain that the filing includes the information the Securities Exchange Act of
1934 and all applicable Exchange Act rules require.   Since the company and its management are
in possession of all facts relating to a company’s disclosure, they are responsible for the accuracy
and adequacy of the disclosures they have made.

In responding to our comment, please provide  a written statement from the company
acknowledging that:

 the company is responsible for the adequacy and accuracy of the disclosure in the filing;
 staff comments or changes to disclosure in response to staff comments do not foreclose
the Commission from taking any action with respect to the filing; and

Scott Cormack
OncoGenex Pharmaceuticals , Inc.
April 9 , 2013
Page 2

 the company  may not assert staff comments as a defense in any proceeding initiated by
the Commission or any person under the federal securities laws of the United States.

You may contac t Johnny Gharib at (202) 551 -3170 , Daniel Greenspan at (202) 551 -3623
or me at (2 02) 551 -3715 with any questions.

Sincerely,

 /s/ Daniel  Greenspan  for

Jeffrey P. Riedler
Assistant Director